OmniaBio will complete CCRM’s continuum of process development, clinical and commercial capabilities, by expanding the offering to include Phase III and commercial-scale manufacturing in a new biomanufacturing campus located in Hamilton, Ontario, less than a one-hour drive from the U.S. border. On October 6, 2022, OmniaBio, CCRM and stakeholders celebrated the commencement of construction at the OmniaBio site.
Read more here.

Live-stream construction progress


OmniaBio’s early-stage CDMO services happen at the cGMP-compliant Centre for Cell and Vector Production (CCVP), located within CCRM in Toronto, Ontario. This GMP-compliant facility provides support to therapy developers by manufacturing cells and viral vectors in a 20,000 sq ft laboratory space with ten clean rooms.
Read more about the CCVP facility, or take a video tour.

The Centre for Advanced Therapeutic Cell Technologies (CATCT) is co-located with the CCVP within CCRM. Here, therapy developers and academic technologies are supported with proof of concept and in vitro experiments, taking place in 10,000 sq ft of laboratory space. The co-location of these two facilities provides a seamless continuity for technologies progressing from the CATCT lab to the CCVP clean rooms.

Read more about the CATCT facility, or take a video tour.